A new oral drug, orforglipron, helped patients lose up to 8% of body weight in one year.
The pill also reduced blood sugar more than oral semaglutide.
Researchers tested over 1,500 adults with type 2 diabetes across five countries.
Participants took daily doses of either treatment for twelve months.
Orforglipron activates GLP-1 receptors, slows digestion, and lowers appetite.
Patients can take it without fasting, which simplifies daily use.
More patients stopped the new drug because of stomach-related side effects.
However, experts see strong potential for an easier, cheaper alternative to injections.
Regulators still review the medication.
Long-term safety and cardiovascular benefits remain uncertain.
Specialists expect powerful oral incretin therapies to reshape diabetes care within the next decade.
